Summary of the pharmacological agents used and basal extracellular glutamate levels in Fig. 1A measured in the rat prefrontal cortex by in vivo microdialysis
Drug | Mechanism of Action | Dose | Basal Glutamate (n) |
|---|---|---|---|
| μM | pmol/sample | ||
| Channels | |||
| TTX | Na+ channel antagonist | 1–10 | 58 ± 10 (4) |
| MVIIC | N/P/Q-type Ca2+ channel antagonist | 10 | 42 ± 3 (4) |
| GVIA | N-type Ca2+ channel antagonist | 10 | 66 + 8 (4) |
| Diltiazem | L-type Ca2+ channel antagonist | 10 | 34 ± 9 (4) |
| EGTA | Ca2+ channel antagonist | 100 | 46 ± 6 (4) |
| AP-5 | NMDA antagonist | 50–500 | 58 ± 8 (5) |
| Transporters | |||
| TBOA | EAAT1–3 antagonist | 10–1000 | 30 ± 4 (5) |
| CPG | mGluR-1/5 and xc- antagonist | 0.5–50 | 55 ± 6 (7) |
| LY367385 | mGluR1/5 antagonist | 0.5–50 | 72 ± 5 (6) |
| HCA | NMDA agonist and xc- antagonist | 1.0–100 | 41 ± 4 (5) |
| mGluRs | |||
| DHPG | mGluR1/5 agonist | 5–50 | 38 ± 3 (7) |
| AIDA | mGluR1/5 antagonist | 50–500 | 45 ± 6 (4) |
| MPEP | mGluR5 antagonist | 5–150 | 43 ± 9 (5) |
| APDC | mGluR2/3 agonist | 50–500 | 53 ± 8 (6) |